Combining Daratumumab with VRd Improves Outcomes in Patients with Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma By Ogkologos - March 3, 2025 770 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CEPHEUS study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Second Interim Analysis Shows OS Improvement with Adjuvant Olaparib for Germline... October 12, 2022 Darolutamide in Combination with ADT and Docetaxel Increases Overall Survival in... February 27, 2023 COVID-19 May Have Saved a Woman’s Life by Helping Her Discover... June 24, 2021 Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance... November 7, 2025 Load more HOT NEWS Research with integrity – referencing work is way more than just... 38% of Recurrent Breast Cancers Have a Different HER2 Status than... Modest Population-Level Increases in Survival Observed After Implementation of Immune Checkpoint... 9/11 Firefighter Dies Of Cancer From Working At Ground Zero
